Clinical-stage biotechnology company developing off-the-shelf allogeneic engineered Tr1 regulatory T-cell therapies to restore immune tolerance and treat autoimmune and inflammatory diseases
Clinical-stage biotechnology company developing off-the-shelf allogeneic engineered Tr1 regulatory T-cell therapies to restore immune tolerance and treat autoimmune and inflammatory diseases. Its pipeline includes TRX103 and CAR-Tr1 programs, with clinical trials for conditions including graft-versus-host disease, refractory Crohn’s disease, noninfectious uveitis, and progressive multiple sclerosis. The company also develops targeted lipid nanoparticle delivery systems for its in vivo CAR-Treg平台